Frequency of Inhibitors among known Hemophilia A Patients.
DOI:
https://doi.org/10.59058/jaimc.v21i2.147Keywords:
Keywords: Hemophilia A, inhibitors, severity.Abstract
ABSTRACT
Introduction: Inhibitors are IgG alloantibodies which are directed against exogenous clotting factor VIII that neutralize the function of infused clotting factor concentrate used for the treatment. The prevalence of inhibitors in Hemophilia A is around 30% worldwide. Inhibitors occurs as a result of natural immune process of the body as factor concentrates used for treatment are foreign to the body and patient’s own body either produces no factor or produces structurally abnormal protein.
Objectives: To determine the frequency of inhibitors among known hemophilia A patients.
Methods: Cross-sectional survey done including 100 male patients of hemophilia A and on treatment for more than 1 year, from 2 to 60 years of age, were included. All the patients were undergone aPTT based screening for inhibitor, both immediately and two hours after mixing the patients plasma with the normal plasma.
Results: Age range in this study was from 2 to 60 years with mean age of 37.21 ± 14.73 years. Frequency of inhibitors among known hemophilia A patients was seen in 18 (18.0%) of cases.
Conclusion: This study concluded that frequency of inhibitors among known hemophilia A patients is quite high.
Keywords: Hemophilia A, inhibitors, severity.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 irem iqbal, Javeria Abdullah
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
